Application of Micropatterned Cocultured Hepatocytes to Evaluate the Inductive Potential and Degradation Rate of Major Xenobiotic Metabolizing Enzymes

Long-term coculture models of hepatocytes are promising tools to study drug transport, clearance, and hepatoxicity. In this report we compare the basal expression of drug disposition genes and the inductive response of prototypical inducers (rifampin, phenobarbital, phenytoin) in hepatocyte two-dimensional monocultures and the long-term coculture model (HepatoPac). All the inducers used in the study increased the expression and activity of CYP3A4, CYP2B6 and CYP2C enzymes in the HepatoPac cultures. The coculture model showed a consistent and higher induction of CYP2C enzymes compared with the monocultures. The EC50 of rifampin for CYP3A4 and CYP2C9 was up to 10-fold lower in HepatoPac than the monocultures. The EC50 of rifampin calculated from the clinical drug interaction studies correlated well with the EC50 observed in the HepatoPac cultures. Owing to the long-term stability of the HepatoPac cultures, we were able to directly measure a half-life (t1/2) for both CYP3A4 and CYP2B6 using the depletion kinetics of mRNA and functional activity. The t1/2 for CYP3A4 mRNA was 26 hours and that for the functional protein was 49 hours. The t1/2 of CYP2B6 was 38 hours (mRNA) and 68 hours (activity), which is longer than CYP3A4 and shows the differential turnover of these two proteins. This is the first study to our knowledge to report the turnover rate of CYP2B6 in human hepatocytes. The data presented here demonstrate that the HepatoPac cultures have the potential to be used in long-term culture to mimic complex clinical scenarios.

[1]  K. Knoell,et al.  Potential Interaction Involving Warfarin and Ritonavir , 1998, The Annals of pharmacotherapy.

[2]  今井 浩光.  The recovery time-course of CYP3A after induction by St. John's wort administration , 2008 .

[3]  R. Obach,et al.  Cytochrome P450 3A4 mRNA Is a More Reliable Marker than CYP3A4 Activity for Detecting Pregnane X Receptor-Activated Induction of Drug-Metabolizing Enzymes , 2010, Drug Metabolism and Disposition.

[4]  Dennis E Discher,et al.  Matrix elasticity, cytoskeletal forces and physics of the nucleus: how deeply do cells ‘feel’ outside and in? , 2010, Journal of Cell Science.

[5]  M. Karlsson,et al.  Pharmacodynamics of Carbamazepine‐mediated Induction of CYP3A4, CYP1A2, and Pgp as Assessed by Probe Substrates Midazolam, Caffeine, and Digoxin , 2008, Clinical pharmacology and therapeutics.

[6]  D. B. Duignan,et al.  Assessment of a Micropatterned Hepatocyte Coculture System to Generate Major Human Excretory and Circulating Drug Metabolites , 2010, Drug Metabolism and Disposition.

[7]  Y. Kobayashi,et al.  Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. , 2011, Biochemical pharmacology.

[8]  Hongbin Yu,et al.  Special Section on Prediction of Human Pharmacokinetic Parameters from In Vitro Systems Meeting the Challenge of Predicting Hepatic Clearance of Compounds Slowly Metabolized by Cytochrome P450 Using a Novel Hepatocyte Model, HepatoPac , 2013 .

[9]  M. Shimizu,et al.  Evaluation of 23 Lots of Commercially Available Cryopreserved Hepatocytes for Induction Assays of Human Cytochromes P450 , 2014, Drug Metabolism and Disposition.

[10]  Hongbing Wang,et al.  Relative Activation of Human Pregnane X Receptor versus Constitutive Androstane Receptor Defines Distinct Classes of CYP2B6 and CYP3A4 Inducers , 2007, Journal of Pharmacology and Experimental Therapeutics.

[11]  V. Garg,et al.  The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers , 2013, British journal of clinical pharmacology.

[12]  A. Poso,et al.  New in vitro tools to study human constitutive androstane receptor (CAR) biology: discovery and comparison of human CAR inverse agonists. , 2011, Molecular pharmaceutics.

[13]  O. J. Trask,et al.  A micropatterned hepatocyte coculture model for assessment of liver toxicity using high-content imaging analysis. , 2014, Assay and drug development technologies.

[14]  M. Gómez-Lechón,et al.  Long‐term expression of differentiated functions in hepatocytes cultured in three‐dimensional collagen matrix , 1998, Journal of cellular physiology.

[15]  R. Kim,et al.  Human Organic Anion Transporting Polypeptide-C (SLC21A6) Is a Major Determinant of Rifampin-Mediated Pregnane X Receptor Activation , 2003, Journal of Pharmacology and Experimental Therapeutics.

[16]  T. Abe,et al.  Screening of antibiotics that interact with organic anion-transporting polypeptides 1B1 and 1B3 using fluorescent probes. , 2011, Biological & pharmaceutical bulletin.

[17]  D. Tweedie,et al.  Determination of a Degradation Constant for CYP3A4 by Direct Suppression of mRNA in a Novel Human Hepatocyte Model, HepatoPac , 2015, Drug Metabolism and Disposition.

[18]  E. Kharasch,et al.  Sensitivity of Intravenous and Oral Alfentanil and Pupillary Miosis as Minimal and Noninvasive Probes for Hepatic and First‐Pass CYP3A Induction , 2011, Clinical pharmacology and therapeutics.

[19]  Hongbing Wang,et al.  Human Constitutive Androstane Receptor Mediates Induction of CYP2B6 Gene Expression by Phenytoin* , 2004, Journal of Biological Chemistry.

[20]  J. Sahi,et al.  Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes , 2009, Journal of biochemical and molecular toxicology.

[21]  J. Goldstein,et al.  Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. , 2001, British journal of clinical pharmacology.

[22]  D. Tweedie,et al.  Generating an In Vitro–In Vivo Correlation for Metabolism and Liver Enrichment of a Hepatitis C Virus Drug, Faldaprevir, Using a Rat Hepatocyte Model (HepatoPac) , 2014, Drug Metabolism and Disposition.

[23]  K. Maeda,et al.  DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1 , 2006, Drug Metabolism and Disposition.

[24]  C. Smith,et al.  Differential Regulation of Hepatic CYP2B6 and CYP3A4 Genes by Constitutive Androstane Receptor but Not Pregnane X Receptor , 2006, Journal of Pharmacology and Experimental Therapeutics.

[25]  J. Goldstein,et al.  The transcriptional regulation of the human CYP2C genes. , 2009, Current drug metabolism.

[26]  Masoud Jamei,et al.  Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. , 2008, Current drug metabolism.

[27]  J. Pascussi,et al.  Transcriptional Regulation of CYP2C9 Gene , 2002, The Journal of Biological Chemistry.

[28]  J. Tredger,et al.  Differential maintenance of cytochrome P450 enzymes in cultured precision-cut human liver slices. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[29]  L. Zhang,et al.  Evaluation of Various Static and Dynamic Modeling Methods to Predict Clinical CYP3A Induction Using In Vitro CYP3A4 mRNA Induction Data , 2014, Clinical pharmacology and therapeutics.

[30]  C Gibson,et al.  Rifampin's Acute Inhibitory and Chronic Inductive Drug Interactions: Experimental and Model‐Based Approaches to Drug–Drug Interaction Trial Design , 2011, Clinical pharmacology and therapeutics.

[31]  M. Toner,et al.  Effect of extracellular matrix topology on cell structure, function, and physiological responsiveness: hepatocytes cultured in a sandwich configuration , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  G. Damm,et al.  3D Cultivation Techniques for Primary Human Hepatocytes , 2015, Microarrays.

[33]  H. Yamazaki,et al.  Fluorescence in situ hybridization analysis of chromosomal localization of three human cytochrome P450 2C genes (CYP2C8, 2C9, and 2C10) at 10q24.1 , 1994, Japanese Journal of Human Genetics.

[34]  M. Mohutsky,et al.  Investigational Small-Molecule Drug Selectively Suppresses Constitutive CYP2B6 Activity at the Gene Transcription Level: Physiologically Based Pharmacokinetic Model Assessment of Clinical Drug Interaction Risk , 2014, Drug Metabolism and Disposition.

[35]  N. Hariparsad,et al.  Cytochrome P450 Enzymes and Transporters Induced by Anti-Human Immunodeficiency Virus Protease Inhibitors in Human Hepatocytes: Implications for Predicting Clinical Drug Interactions , 2007, Drug Metabolism and Disposition.

[36]  A. Callendrello,et al.  Evaluation of Calibration Curve–Based Approaches to Predict Clinical Inducers and Noninducers of CYP3A4 with Plated Human Hepatocytes , 2014, Drug Metabolism and Disposition.

[37]  M. Niemi,et al.  Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin , 2006, Pharmacogenetics and genomics.